Jasmeet Singh to Immunoconjugates
This is a "connection" page, showing publications Jasmeet Singh has written about Immunoconjugates.
Connection Strength
0.515
-
Lu Z, Wada R, Salas M, Singh J, Kawaguchi Y, Belli AJ, Abutarif M, Garimella T. Use of Real-World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2-Targeted Antibody-Drug Conjugate in Gastric Cancer. J Clin Pharmacol. 2023 Nov; 63(11):1244-1255.
Score: 0.198
-
Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug; 183(1):23-39.
Score: 0.160
-
Tsurutani J, Iwata H, Krop I, J?nne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020 05; 10(5):688-701.
Score: 0.157